Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 12.20 is 105% above its 5-year average of 5.96, near the low end of its 5-year range (-21.91–100.11).
As of the fiscal period ended Tuesday, June 30, 2026. 9.48% below its 12-month average of 13.48.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 12.20.
DEBT TO EQUITY RATIO
12.20
DEBT TO EQUITY RATIO AVG TTM
13.48
DEBT TO EQUITY RATIO AVG 3Y
8.57
DEBT TO EQUITY RATIO AVG 5Y
5.96
DEBT TO EQUITY RATIO AVG 10Y
3.06
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-9.48%
CURRENT VS 3Y AVG
+42.32%
CURRENT VS 5Y AVG
+104.82%
CURRENT VS 10Y AVG
+298.86%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 570 covered companies
CURRENT VS SECTOR MEDIAN
+9287.06%
vs the sector median at left
Establishment Labs Holdings Inc.
Market Cap
$1.95B
Debt to Equity Ratio
12.20
TTM Avg
13.48
3Y Avg
8.57
5Y Avg
5.96
Market Cap
$1.99B
Debt to Equity Ratio
0.04
TTM Avg
0.04
3Y Avg
0.04
5Y Avg
0.07
Market Cap
$2.03B
Debt to Equity Ratio
0.18
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$2.02B
Debt to Equity Ratio
0.10
TTM Avg
0.17
3Y Avg
0.15
5Y Avg
0.11
Market Cap
$1.89B
Debt to Equity Ratio
0.04
TTM Avg
0.07
3Y Avg
0.09
5Y Avg
0.08
Market Cap
$1.88B
Debt to Equity Ratio
0.03
TTM Avg
0.04
3Y Avg
0.06
5Y Avg
0.10
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Establishment Labs Holdings Inc. (ESTA) | $1.95B | 12.20 | 13.48 | 8.57 | 5.96 |
| Immunome, Inc. (IMNM)vs › | $1.96B | 0.01 | 0.02 | 0.02 | 0.01 |
| AxoGen, Inc. (AXGN)vs › | $1.95B | 0.08 | 0.59 | 0.64 | 0.60 |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.99B | 0.04 | 0.04 | 0.04 | 0.07 |
| Azenta, Inc. (AZTA)vs › | $1.90B | 0.04 | 0.05 | 0.03 | 0.05 |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $2.03B | 0.18 | 0.00 | 0.00 | 0.00 |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 0.10 | 0.17 | 0.15 | 0.11 |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 0.04 | 0.07 | 0.09 | 0.08 |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.88B | 0.03 | 0.04 | 0.06 | 0.10 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.03B | N/A | 2.21 | 2.21 | 2.21 |
Debt/Equity
12.20
Current Ratio
3.84
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 12.20 |
| 2026-03-31 | 17.86 |
| 2025-12-31 | 11.23 |
| 2025-09-30 | 15.96 |
| 2025-06-30 | 10.15 |
| 2025-03-31 | 5.85 |
| 2024-12-31 | 4.24 |
| 2024-09-30 | 6.09 |
| 2024-06-30 | 4.39 |
| 2024-03-31 | 3.45 |
| 2023-12-31 | 10.45 |
| 2023-09-30 | 6.20 |
| 2023-06-30 | 3.39 |
| 2023-03-31 | -11.43 |
| 2022-12-31 | -21.91 |
| 2022-09-30 | 100.11 |
| 2022-06-30 | 9.30 |
| 2022-03-31 | 1.14 |
| 2021-12-31 | 1.07 |
| 2021-09-30 | 0.87 |
| 2021-06-30 | 0.78 |
| 2021-03-31 | 0.73 |
| 2020-12-31 | 0.70 |
| 2020-09-30 | 0.62 |
| 2020-06-30 | 0.60 |
| 2020-03-31 | 0.54 |
| 2019-12-31 | 1.22 |
| 2019-09-30 | 1.09 |
| 2019-06-30 | 0.45 |
| 2019-03-31 | 0.38 |
| 2018-12-31 | 0.32 |
| 2018-09-30 | 0.28 |
| 2018-06-30 | 10.86 |
| 2018-03-31 | -2.84 |
| 2017-12-31 | -4.81 |
| 2017-09-30 | 0.00 |
| 2017-06-30 | 0.00 |
| 2017-03-31 | 0.00 |
